Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Positive)

Key Terms

glucose biosensing medical

Glucose biosensing is the use of a biological or chemical sensor to detect and measure blood sugar levels, typically through a small device or patch that reads body fluids and converts that signal into a readable number. Investors care because these sensors can drive steady revenue from devices and consumables, change how chronic diseases are managed, and face regulatory and adoption hurdles similar to launching a new consumer gadget — think of it as a reliable meter that tells you how your body’s fuel is behaving.

continuous glucose monitoring medical

Continuous glucose monitoring is a system that tracks blood sugar levels in real-time throughout the day and night. It provides constant updates, similar to a car's dashboard showing speed and fuel level at all times. For investors, advancements in this technology can signal progress in health monitoring devices, which may influence the growth and valuation of companies in the healthcare sector.

type 1 diabetes medical

An autoimmune condition in which the pancreas stops producing insulin, a hormone that lets the body use sugar for energy; without insulin people must manage blood sugar with injections, pumps, or other therapies. For investors, it matters because the lifelong need for medicines, devices, and monitoring creates steady demand, influences healthcare spending and reimbursement decisions, and drives clinical trials and regulatory activity in the diabetes treatment market.

type 2 diabetes medical

Type 2 diabetes is a chronic condition where the body struggles to control blood sugar levels because it becomes less responsive to insulin, a hormone that helps regulate sugar in the blood. It matters to investors because it can lead to increased healthcare costs, affect workforce productivity, and influence the performance of companies in the healthcare and pharmaceutical sectors. Managing or preventing the condition has significant implications for public health and economic stability.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

06/02/2026 - 06:30 AM

Company establishes permanent council to drive ongoing innovation guided by community feedback
Report outlines targeted commitments Dexcom is making to address sentiments shared by council members

SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc., the global leader in glucose biosensing, today released its inaugural Customer Advisory Council Report, detailing candid feedback from users, caregivers, healthcare professionals and community leaders, along with clear, actionable company commitments to further elevate product performance and user experience. Building on its position as the manufacturer of the most accurate CGM systems¹, Dexcom continues to listen, innovate and act on customer insights to strengthen its technology and reinforce its leadership as the premier choice for people with diabetes, globally.

Report outlines targeted commitments Dexcom is making to address sentiments shared by council members

Formed in January 2026, the Dexcom Customer Advisory Council brings together a diverse group of stakeholders – people with Type 1 and Type 2 diabetes, caregivers, diabetes educators, healthcare professionals and community advocates from around the world – to create a direct and ongoing dialogue with the people who depend on Dexcom products every day.

"Dexcom has pioneered and set the global standard for continuous glucose monitoring, and we are deeply committed to continually raising that standard to meet the evolving needs of our community," said Jake Leach, president and chief executive officer of Dexcom. "This council represents our belief that the best path forward is through listening – truly hearing what's working and what isn't. We will continue to be transparent, responsive and relentless in our pursuit of earning and maintaining the trust of our users every day."

Through independent moderation by Vital Findings, council members reinforced that Dexcom remains a life-changing, essential technology that has improved millions of lives. They also identified opportunities to improve product reliability, customer service and communication, prompting six concrete commitments outlined in the report:

Delivering the best possible product by continuously improving the performance of every Dexcom sensor.
Making sure product replacements are easier, replacing any sensor confirmed as a product failure without limit and offering self-service ways to request replacements.
Raising the bar for customer service, making the experience more human, informed and responsive.
Making the Customer Advisory Council a permanent part of how Dexcom does business.
Communicating more clearly and transparently, including product updates, company news and issues (good or bad).
Creating a new content series that demystifies the science and technology behind CGM.

The council will continue to meet throughout 2026, with regular public updates on progress against commitments. The full Customer Advisory Council Community Commitment Report, including in-depth discussions on accuracy, connectivity, adhesives and more, is available at dexcom.com/about-dexcom.

Toward the end of 2026, Dexcom will announce the format and approach for the continuation of the Customer Advisory Council in 2027 and beyond.

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

¹ Dexcom, Data on File, 2025